BioPharm International sat down with Kevin Isett, PhD, co-founder and CEO of Avitide, to find out why he thinks the company’s tailored approach to purification resins will change the face of biopharmaceutical separation.

The lessons that Kevin Isett learned during his time at Adimab, a therapeutic antibody discovery technology company, were top of mind when Isett embarked on the development of a novel purification technology. Rather than making the product first and figuring out which markets to target, working at Adimab gave him the insight to understand the value of building a technology platform to address precise industry need. Despite the fact that the bioprocessing industry is conservative and highly regulated, according to Isett, Avitide was able to draw from community feedback to drive the development of its service offerings and capabilities.

Read More